Cyrano Therapeutics, Inc

Cyrano Therapeutics, Inc., based in Delray Beach, FL, is dedicated to developing pharmaceutical therapies aimed at addressing long-term loss of smell and taste, a condition that has significantly increased in prevalence since the COVID-19 pandemic. With over 15 million people in the U.S. affected prior to the pandemic, and thousands of new cases emerging daily, the company is committed to advancing solutions that restore these essential senses and enhance the quality of life for those impacted.

The company is currently conducting a 32-week randomized double-blinded placebo-controlled clinical trial to evaluate the safety and effectiveness of CYR064 as a potential treatment for hyposmia, or partial loss of smell. By rigorously testing the impact of CYR064 on restoring olfactory function, Cyrano Therapeutics aims to contribute valuable insights into the treatment of olfactory disorders, which can significantly affect individuals' quality of life, safety, and mental health.

Generated from the website